ProCE Banner Activity

Risk Assessment and Ki-67 Testing in HR-Positive/HER2-Negative EBC for Adjuvant Abemaciclib

Slideset Download
This slideset accompanies an expert analysis of the role of Ki-67 in risk assessment and discusses recently approved adjuvant abemaciclib for patients with HR-positive, HER2-negative EBC at high risk of recurrence.

Released: May 12, 2022

Expiration: May 11, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Lilly

Merck Sharp & Dohme Corp.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Yara Abdou, MD

Assistant Professor, Division of Oncology
Breast Cancer Clinical Trial Program Leader
University of North Carolina at Chapel Hill
Lineberger Comprehensive Cancer Center 
Chapel Hill, North Carolina